Blocking enzyme cuts toxic Parkinson’s effects in models, University of Cambridge researchers discover

Blocking enzyme cuts toxic Parkinson’s effects in models, University of Cambridge researchers discover

The metabolic driver of the disease offers a promising new drug target.

RNA-editing enzyme ADAR1 may be new Parkinson's target

The dysregulation of RNA editing within astrocytes (neuron-supporting cells) seems to induce chronic inflammation and ultimately contributes to the loss of nerve cells in people with Parkinson’s disease, according to a recent study. This dysregulation is triggered by alpha-synuclein clumping, which is a characteristic feature of Parkinson’s. RNA editing refers to changes in the sequence of messenger RNA — the intermediate molecule derived from D…